Company Name, Ticker, Industry, else..

Aravive Inc (NASDAQ: ARAV)

Sector • Healthcare Industry • Major Pharmaceutical Preparations

Industry • Major Pharmaceutical Preparations

Sector • Healthcare

Aravive Inc 's

Name: Aravive Inc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

ARAV Sales vs. its Competitors Q3 2023

Comparing the current results to its competitors, Aravive Inc reported Revenue decrease in the 3 quarter 2023 year on year by -44.39 %, despite the revenue increase by the most of its competitors of 46.99 %, recorded in the same quarter.

• List of ARAV Competitors

With a net margin of 770.17 % Aravive Inc achieved higher profitability than its competitors.

• More on ARAV Profitability Comparisons

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

Aravive Inc achieved net profit of $21.23 millions compared to a net loss of $-15.66 millions recorded in the same quarter a year ago.

<< ARAV Stock Performance Comparisons

<< See the full list of ARAV competitors

Overall company Market Share Q3 2023

Overall company, revenue fell by -44.39 % and company lost market share, to approximately 0.19 %. << More on ARAV Market Share.

*Market share is calculated based on total revenue.

ARAV's Stock Performance relative to its Competitors

Publicly Traded Peers of Aravive Inc

Zai Lab Limited
Share Performance

+45.87%

This Year

Zai Lab Limited

Profile

Zai Lab Limited operates as a biopharmaceutical company primarily in China. The company seeks to discover, develop, and commercialize innovative medicines to address unmet medical needs in the country. Zai Lab focuses on licensing and acquiring clinical stage or late-stage development drugs, and then progressing them through regulatory approval and commercial launch.

More about Zai Lab Limited's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 2,799.484 mill.	$ 453.280 mill.	$ -178.115 mill.

Nucana Plc
Share Performance

-52.01%

One Year

Nucana Plc

Profile

Nucana Plc is a pharmaceutical company that focuses on developing novel treatments for cancer and other diseases.

More about Nucana Plc's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ - mill.	$ - mill.	$ -29.353 mill.

Neubase Therapeutics inc
Share Performance

-43.58%

This Quarter

Neubase Therapeutics inc

Profile

Neubase Therapeutics Inc is a biotechnology company focused on developing and commercializing small molecule therapies for genetic diseases. They aim to leverage their proprietary modular antisense oligonucleotide platform to create therapeutics that can specifically target and treat multiple genetic diseases.

More about Neubase Therapeutics inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 1.042 mill.	$ - mill.	$ -13.730 mill.

Mirati Therapeutics Inc
Share Performance

+3.77%

This Quarter

Mirati Therapeutics Inc

Profile

Mirati Therapeutics Inc is a biotechnology company that focuses on the research, discovery, and development of precision oncology treatments for patients with cancer. Their business model involves leveraging their proprietary drug discovery platform to identify and develop targeted therapies, and collaborating with partners for the commercialization of their products.

More about Mirati Therapeutics Inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 3,815.094 mill.	$ 38.191 mill.	$ -725.878 mill.

Mersana Therapeutics inc
Share Performance

+273.56%

This Quarter

Mersana Therapeutics inc

Profile

Mersana Therapeutics Inc's business model focuses on developing and commercializing novel antibody-drug conjugates (ADCs) for the treatment of cancer.

More about Mersana Therapeutics inc 's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 145.286 mill.	$ 33.180 mill.	$ -70.081 mill.

46 more competitors available

Sources: Aravive Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Tuesday, September 1, 2026 6:01 AM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Aravive Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.